Compare GGRP & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GGRP | HOWL |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5M | 15.7M |
| IPO Year | 2021 | 2021 |
| Metric | GGRP | HOWL |
|---|---|---|
| Price | $0.90 | $0.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 104.7K | ★ 902.9K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.42 | $0.27 |
| 52 Week High | $1.08 | $2.23 |
| Indicator | GGRP | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 62.78 |
| Support Level | $0.73 | $0.40 |
| Resistance Level | $0.91 | $0.75 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 48.34 | 93.66 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.